| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2106 | 2017 |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1527 | 2018 |
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ... Journal of viral hepatitis 21, 34-59, 2014 | 565 | 2014 |
| Historical epidemiology of hepatitis C virus (HCV) in selected countries P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ... Journal of viral hepatitis 21, 5-33, 2014 | 415 | 2014 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 350 | 2022 |
| Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial J Grebely, O Dalgard, B Conway, EB Cunningham, P Bruggmann, ... The lancet Gastroenterology & hepatology 3 (3), 153-161, 2018 | 308 | 2018 |
| Strategies to manage hepatitis C virus (HCV) disease burden H Wedemeyer, AS Duberg, M Buti, WM Rosenberg, S Frankova, G Esmat, ... Journal of viral hepatitis 21, 60-89, 2014 | 274 | 2014 |
| Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all P Bruggmann, AH Litwin Clinical Infectious Diseases 57 (suppl_2), S56-S61, 2013 | 221 | 2013 |
| Recommendations for the management of hepatitis C virus infection among people who inject drugs J Grebely, G Robaeys, P Bruggmann, A Aghemo, M Backmund, ... International Journal of Drug Policy 26 (10), 1028-1038, 2015 | 208 | 2015 |
| Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe AD Marshall, EB Cunningham, S Nielsen, A Aghemo, H Alho, ... The lancet Gastroenterology & hepatology 3 (2), 125-133, 2018 | 166 | 2018 |
| Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework E Day, M Hellard, C Treloar, J Bruneau, NK Martin, A Øvrehus, O Dalgard, ... Liver International 39 (1), 20-30, 2019 | 142 | 2019 |
| Recommendations for the management of hepatitis C virus infection among people who inject drugs G Robaeys, J Grebely, S Mauss, P Bruggmann, J Moussalli, A De Gottardi, ... Clinical Infectious Diseases 57 (suppl_2), S129-S137, 2013 | 136 | 2013 |
| Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers P Bruggmann Journal of viral hepatitis 19 (12), 829-835, 2012 | 118 | 2012 |
| Prevention, treatment and care of hepatitis C virus infection among people who inject drugs P Bruggmann, J Grebely International Journal of Drug Policy 26, S22-S26, 2015 | 113 | 2015 |
| Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients P Bruggmann, L Falcato, S Dober, B Helbling, O Keiser, F Negro, D Meili, ... Journal of viral hepatitis 15 (10), 747-752, 2008 | 91 | 2008 |
| Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study EB Cunningham, J Amin, JJ Feld, J Bruneau, O Dalgard, J Powis, ... International journal of drug policy 62, 14-23, 2018 | 83 | 2018 |
| Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs J Grebely, J Bruneau, JV Lazarus, O Dalgard, P Bruggmann, C Treloar, ... International Journal of Drug Policy 47, 51-60, 2017 | 78 | 2017 |
| Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study D Razavi-Shearer, I Gamkrelidze, C Pan, J Jia, T Berg, R Gray, YS Lim, ... The Lancet Gastroenterology & Hepatology 8 (10), 879-907, 2023 | 71 | 2023 |
| Prevalence of hepatitis C in a Swiss sample of men who have sex with men: whom to screen for HCV infection? AJ Schmidt, L Falcato, B Zahno, A Burri, S Regenass, B Müllhaupt, ... BMC Public Health 14, 1-11, 2014 | 70 | 2014 |
| Hepatitis B and C in Switzerland–healthcare provider initiated testing for chronic hepatitis B and C infection R Fretz, F Negro, P Bruggmann, D Lavanchy, A De Gottardi, I Pache, ... Swiss medical weekly 143 (1920), w13793-w13793, 2013 | 67 | 2013 |
